Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven O'Reilly

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
Cytokine|June 6, 2022
Interleukin-36α is elevated in diffuse systemic sclerosis and may potentiate fibrosisSteven O'Reilly
Internal Medicine Journal|July 19, 2021
Serum amyloid A as a universal biomarker in lung diseaseSteven O'Reilly
The British Journal of Dermatology|October 9, 2024
May the force be with you: targeting mechanical forces in keloidsSteven O'Reilly
Annals of the Rheumatic Diseases|May 31, 2019
Epigenetic regulation of RUNX3 in systemic sclerosis pathogenesis: time to target?Steven O'Reilly
Rheumatology (Oxford, England)|March 27, 2018
Epigenetic modulation as a therapy in systemic sclerosisSteven O'Reilly
Matrix Biology : Journal of the International Society for Matrix Biology|January 14, 2024
S100A4 a classical DAMP as a therapeutic target in fibrosisSteven O'Reilly
Journal of Immunology (Baltimore, Md. : 1950)|April 3, 2025
The metabolic drivers of IFN-γ release: glycolysis and acetyl CoA ride in the front seatJohn Henderson, Steven O'Reilly
The Journal of Investigative Dermatology|April 17, 2017
Toxic Memories in Systemic SclerosisLaura Duffy, Steven O'Reilly
Seminars in Immunopathology|July 11, 2015
Role of innate immune system in systemic sclerosisNicola Fullard, Steven O'Reilly
Mediators of Inflammation|September 6, 2016
Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesMarzena Ciechomska, Steven O'Reilly
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
Cytokine|June 6, 2022
Interleukin-36α is elevated in diffuse systemic sclerosis and may potentiate fibrosisSteven O'Reilly
Internal Medicine Journal|July 19, 2021
Serum amyloid A as a universal biomarker in lung diseaseSteven O'Reilly
The British Journal of Dermatology|October 9, 2024
May the force be with you: targeting mechanical forces in keloidsSteven O'Reilly
Annals of the Rheumatic Diseases|May 31, 2019
Epigenetic regulation of RUNX3 in systemic sclerosis pathogenesis: time to target?Steven O'Reilly
Rheumatology (Oxford, England)|March 27, 2018
Epigenetic modulation as a therapy in systemic sclerosisSteven O'Reilly
Matrix Biology : Journal of the International Society for Matrix Biology|January 14, 2024
S100A4 a classical DAMP as a therapeutic target in fibrosisSteven O'Reilly
Journal of Immunology (Baltimore, Md. : 1950)|April 3, 2025
The metabolic drivers of IFN-γ release: glycolysis and acetyl CoA ride in the front seatJohn Henderson, Steven O'Reilly
The Journal of Investigative Dermatology|April 17, 2017
Toxic Memories in Systemic SclerosisLaura Duffy, Steven O'Reilly
Seminars in Immunopathology|July 11, 2015
Role of innate immune system in systemic sclerosisNicola Fullard, Steven O'Reilly
Mediators of Inflammation|September 6, 2016
Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesMarzena Ciechomska, Steven O'Reilly
Pageof 9